Co-Diagnostics to Present at Medical Korea 2026

Rhea-AI Summary

Co-Diagnostics (Nasdaq: CODX) will join a Utah delegation at Medical Korea 2026 in Seoul, March 19–22, 2026. Co-Dx will participate in a healthcare roundtable on March 19 and present its upcoming Co-Dx PCR point-of-care platform. Attendance is partly supported by a WTC Utah grant.

The Co-Dx PCR platform remains under regulatory review and is not yet available for sale.

AI-generated analysis. Not financial advice.

News Market Reaction – CODX

-10.00%

19 alerts

-10.00% News Effect

-15.7% Trough in 31 hr 30 min

-$631K Valuation Impact

$5.68M Market Cap

0.4x Rel. Volume

On the day this news was published, CODX declined 10.00%, reflecting a significant negative market reaction. Argus tracked a trough of -15.7% from its starting point during tracking. Our momentum scanner triggered 19 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $631K from the company's valuation, bringing the market cap to $5.68M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Conference dates: March 19-22, 2026 Expected participants: more than 6,000 Participating countries: over 50 countries +1 more

4 metrics

Conference dates March 19-22, 2026 Medical Korea 2026 in Seoul, South Korea

Expected participants more than 6,000 Attendees at Medical Korea 2026 from over 50 countries

Participating countries over 50 countries Global reach of Medical Korea 2026 conference

Conference edition 16th annual Medical Korea 2026: Global Healthcare & Medical Tourism Conference

Market Reality Check

Price: $9.11 Vol: Volume 1,076,527 is about...

high vol

$9.11 Last Close

Volume Volume 1,076,527 is about 4.29x the 20-day average of 250,967, signaling elevated trading interest ahead of the event. high

Technical Shares at 2.8 are trading below the 200-day MA of 8.17, indicating a longer-term downtrend despite today’s bounce.

Peers on Argus

Momentum data flags only XAIR with notable action, down about 2.9%, while other ...

1 Down

Momentum data flags only XAIR with notable action, down about 2.9%, while other medical device peers show mixed, smaller moves. This points to a stock-specific reaction rather than a broad sector shift.

Historical Context

5 past events · Latest: Mar 12 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 12	Patent grant Japan	Positive	-18.8%	Japan patent with 34 claims covering Co-Dx PCR Pro technologies.
Mar 10	Nasdaq compliance	Positive	+101.8%	Regained Nasdaq listing compliance including $1.00 bid price requirement.
Feb 09	Expo participation	Positive	-4.7%	Showcasing upcoming Co-Dx PCR platform at Dubai World Health Expo Labs.
Feb 05	India license	Positive	+0.0%	CoSara receives CDSCO license to manufacture and sell PCR Pro instrument.
Feb 04	ISO certification	Positive	+0.0%	CoSara gains ISO 13485:2016 certification for PCR platform manufacturing prep.

Pattern Detected

Recent CODX news often showed price moves that diverged from seemingly positive operational updates, with only the Nasdaq compliance announcement aligning clearly with a strong upside move.

Recent Company History

Over the last few months, CODX has focused on its Co-Dx PCR point-of-care platform and global positioning. A Mar 10 notice of regaining Nasdaq compliance drove a 101.83% move, while a Japanese patent grant on Mar 12 and showcasing the platform in Dubai and India drew flat to negative reactions. Today’s Medical Korea 2026 presentation extends that theme of international exposure and commercialization groundwork for the platform, which remains under regulatory review.

Market Pulse Summary

The stock dropped -10.0% in the session following this news. A negative reaction despite conference ...

Analysis

The stock dropped -10.0% in the session following this news. A negative reaction despite conference participation would fit CODX’s history of weak follow-through on seemingly positive operational news, such as the Japanese patent and Dubai expo updates that saw flat to negative moves. The Medical Korea 2026 event expands international visibility for the Co-Dx PCR platform, but the product still awaited regulatory clearance and commercialization, leaving the market cautious about near-term revenue impact from marketing-focused announcements.

Key Terms

molecular diagnostics, pcr, point-of-care, b2b, +2 more

6 terms

molecular diagnostics medical

"a molecular diagnostics company with a unique, patented platform"

Molecular diagnostics are laboratory tests that look for specific molecules — such as genes, pieces of DNA or RNA, or proteins — to detect disease, predict risk, or guide treatment choices. For investors, these tests matter because they can change how illnesses are diagnosed and treated, create recurring revenue through specialized tests and companion products, and face clear regulatory and reimbursement pathways that drive commercial value; think of them as reading a biological barcode to inform medical decisions.

pcr medical

"upcoming Co-Dx PCR point-of-care platform*"

PCR (polymerase chain reaction) is a laboratory method that makes many copies of a tiny piece of genetic material (DNA or RNA) so scientists can detect and study it reliably — think of photocopying a faint, tiny note until the words are easy to read. For investors, PCR matters because it underpins diagnostic tests, drug development, and biotech tools whose sales, regulatory approvals, and real-world use can materially affect company revenues and market perceptions during health events or product launches.

point-of-care medical

"upcoming Co-Dx PCR point-of-care platform*"

"Point-of-care" refers to the location where immediate decision-making or actions happen, often involving the direct delivery of services or results. In healthcare, it describes tests or treatments performed directly at the patient's side, rather than in a distant laboratory. For investors, understanding "point-of-care" highlights the convenience, speed, and potential growth opportunities of services or products that bring solutions directly to the user or patient.

b2b financial

"will also include B2B introduction opportunities, presentations and special sessions."

Business-to-business (B2B) describes companies that sell products or services to other businesses rather than to individual consumers. For investors, B2B models often mean larger, repeatable contracts and revenue tied to corporate budgets, which can produce steadier, more predictable cash flow; think of a parts supplier selling regular batches to a factory rather than a shop selling single items to walk-in customers, so customer concentration and contract length matter.

mobile app technical

"including the PCR Home®, PCR Pro®, mobile app, and all associated tests"

A mobile app is a software program designed to run on smartphones and tablets, delivering services, information or transactions directly to a user's device. For investors, mobile apps matter because they act like a storefront or service counter in someone’s pocket—driving user engagement, recurring revenue, customer retention and data collection—so an app’s adoption, costs and monetization can materially influence a company’s sales, profitability and valuation.

fda regulatory

"subject to review by the FDA and/or other regulatory bodies"

The FDA is the U.S. federal agency that evaluates and approves medical drugs, devices, biological therapies and certain foods; think of it as the gatekeeper that decides whether a medical product is safe and effective for patients. For investors, FDA decisions determine whether a company can sell a product, affect expected revenue and introduce regulatory risk, so approvals, rejections or safety warnings can quickly move a company's valuation and stock price.

AI-generated analysis. Not financial advice.

Co-Dx to join WTC Utah and other Utah legislative and industry delegates March 19-22 in Seoul, South Korea

SALT LAKE CITY, March 16, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that Co-Dx will accompany World Trade Center (WTC) Utah, the Utah Governor's Office of Economic Opportunity (GOEO), BioUtah, and other legislative and industry leaders at Medical Korea 2026, taking place March 19-22 in Seoul, South Korea.

Co-Dx will participate in a healthcare business roundtable on March 19th and will conduct a presentation highlighting the Company's upcoming Co-Dx PCR point-of-care platform*. This year's conference is expected to draw more than 6,000 participants from over 50 countries and will also include B2B introduction opportunities, presentations and special sessions.

Participants are invited to visit Co-Dx at the State of Utah booth to learn more about the Company's innovative point-of-care infectious disease diagnostics solutions and how it aligns with the conference theme of "AI-Powered Global Healthcare: Bringing the Future and the World Closer."

David Carlebach, COO of WTC Utah, remarked, "South Korea is a priority partner for Utah as both regions work to strengthen a growing trade and investment corridor. To support that effort, World Trade Center Utah and the Utah Governor's Office of Economic Opportunity have established a team in Seoul focused on expanding Utah's presence and partnerships in the market."

"WTC Utah is organizing the delegation to attend this conference, connecting Utah companies with partners across South Korea's dynamic healthcare ecosystem," continued Carlebach. "Medical Korea provides a strong platform to advance Utah–South Korea collaboration in healthcare and life sciences, and we look forward to engaging with our partners at the event."

The Company's travel and attendance at the conference is made possible in part by a grant from WTC Utah, the official international business promotion organization for the Utah GEOE, which regularly conducts trade missions worldwide to connect Utah businesses with global partners and resources.

The 16^th annual Medical Korea 2026: Global Healthcare & Medical Tourism Conference, hosted in Seoul, South Korea, brings together international healthcare leaders, government officials, and industry innovators. The event serves as a premier platform for advancing global healthcare collaborations and highlighting emerging medical technologies, fostering cross-border partnerships in healthcare and life sciences.

*The Co-Dx PCR platform (including the PCR Home®, PCR Pro®, mobile app, and all associated tests) is subject to review by the FDA and/or other regulatory bodies and is not yet available for sale.

About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory review and not currently cleared for sale) and to identify genetic markers for use in applications other than infectious disease.

Company Contact:                                                            
Andrew Benson                                                                           
Head of Investor Relations                                                 
+1 801.438.1036                                                                                   
investors@codiagnostics.com                                             

Investor Contact:
Valter Pinto, Managing Director
KCSA Strategic Communications
+1 212.896.1254
CODX@KCSA.com

Media Contact:
Jennifer Webb
ColtrinMethod PR  
jcoltrin@coltrinmethodpr.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-to-present-at-medical-korea-2026-302714308.html

SOURCE Co-Diagnostics

FAQ

When will Co-Diagnostics (CODX) present at Medical Korea 2026 in Seoul?

Co-Diagnostics will present on March 19, 2026 at Medical Korea 2026 in Seoul. According to Co-Dx, the company will join a Utah delegation and participate in a healthcare business roundtable that day to highlight its point-of-care PCR platform.

What will Co-Diagnostics showcase about the Co-Dx PCR platform at Medical Korea 2026 (CODX)?

Co-Diagnostics will highlight its upcoming Co-Dx PCR point-of-care platform, including PCR Home and PCR Pro. According to Co-Dx, the presentation will describe the platform and related diagnostics while noting the products are under regulatory review and not yet for sale.

Where can visitors find Co-Diagnostics (CODX) during Medical Korea 2026?

Visitors can find Co-Diagnostics at the State of Utah booth during Medical Korea 2026. According to Co-Dx, the booth will host discussions on the company’s infectious disease diagnostics and B2B introduction opportunities with conference attendees.

Is the Co-Dx PCR platform available for sale after the March 2026 presentation (CODX)?

No, the Co-Dx PCR platform is not yet available for sale and remains under regulatory review. According to Co-Dx, the platform including PCR Home, PCR Pro, mobile app and tests is subject to FDA and other regulatory review before commercialization.

Why is Co-Diagnostics (CODX) attending Medical Korea 2026 with a Utah delegation?

Co-Diagnostics is attending to expand partnerships and showcase diagnostics in South Korea’s healthcare market. According to Co-Dx, participation is supported in part by a WTC Utah grant and aims to connect the company with regional healthcare and life sciences partners.